Measuring molecular biomarkers in epidemiologic studies: Laboratory techniques and biospecimen considerations

Statistics in Medicine

Volumn 31, Issue 22, 2012, Pages 2400-2413

  Erickson, Heidi S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biospecimens; Genetic epidemiology; High throughput molecular biomarker analysis; Population based studies; Sample pooling

Indexed keywords

BIOLOGICAL MARKER; GENOMIC DNA; PHOSPHATIDYLINOSITOL 3 KINASE; RNA; XENOBIOTIC AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HIGH THROUGHPUT SCREENING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MET GENE; MICROARRAY ANALYSIS; PIK3CA GENE; POPULATION GENETICS; PROTEIN ANALYSIS; PROTEOMICS; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS;

BIOLOGICAL MARKERS; CLINICAL LABORATORY TECHNIQUES; EPIDEMIOLOGIC METHODS; HUMANS; SPECIMEN HANDLING;

EID: 84866142750     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4485     Document Type: Article

References (108)

1. Group BDW. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 2001; 69:89-95. DOI: 10.1067/mcp.2001.113989.
2. Erickson HS, Gannot G, Tangrea MA, Chuaqui RF, Gillespie JW, Emmert-Buck MR. High throughput screening of normal and neoplastic tissue samples. Combinatorial Chemistry & High Throughput Screening 2010; 13:253-267.
3. Wactawski-Wende J, Schisterman EF, Hovey KM, Howards PP, Browne RW, Hediger M, Liu A, Trevisan M. BioCycle study: design of the longitudinal study of the oxidative stress and hormone variation during the menstrual cycle. Paediatric and Perinatal Epidemiology 2009; 23:171-184. DOI: 10.1111/j.1365-3016.2008.00985.x.
4. Mordukhovich I, Wilker E, Suh H, Wright R, Sparrow D, Vokonas PS, Schwartz J. Black carbon exposure, oxidative stress genes, and blood pressure in a repeated-measures study. Environmental Health Perspectives 2009; 117:1767-1772. DOI: 10.1289/ehp.0900591.
5. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. New England Journal of Medicine 2005; 352:2184-2192. DOI: 10.1056/NEJMoa043792.
6. Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S, Chandler I, Vijayakrishnan J, Sullivan K, Penegar S, Carvajal-Carmona L, Howarth K, Jaeger E, Spain SL, Walther A, Barclay E, Martin L, Gorman M, Domingo E, Teixeira AS, Kerr D, Cazier JB, Niittymaki I, Tuupanen S, Karhu A, Aaltonen LA, Tomlinson IP, Farrington SM, Tenesa A, Prendergast JG, Barnetson RA, Cetnarskyj R, Porteous ME, Pharoah PD, Koessler T, Hampe J, Buch S, Schafmayer C, Tepel J, Schreiber S, Volzke H, Chang-Claude J, Hoffmeister M, Brenner H, Zanke BW, Montpetit A, Hudson TJ, Gallinger S, Campbell H, Dunlop MG. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nature Genetics 2008; 40:1426-1435. DOI: 10.1038/ng.262.
7. Bennett WP, Alavanja MC, Blomeke B, Vahakangas KH, Castren K, Welsh JA, Bowman ED, Khan MA, Flieder DB, Harris CC. Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. Journal of the National Cancer Institute 1999; 91:2009-2014.
8. Fend F, Emmert-Buck MR, Chuaqui R, Cole K, Lee J, Liotta LA, Raffeld M. Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. American Journal of Pathology 1999; 154:61-66.
9. Gillespie JW, Best CJ, Bichsel VE, Cole KA, Greenhut SF, Hewitt SM, Ahram M, Gathright YB, Merino MJ, Strausberg RL, Epstein JI, Hamilton SR, Gannot G, Baibakova GV, Calvert VS, Flaig MJ, Chuaqui RF, Herring JC, Pfeifer J, Petricoin EF, Linehan WM, Duray PH, Bova GS, Emmert-Buck MR. Evaluation of non-formalin tissue fixation for molecular profiling studies. American Journal of Pathology 2002; 160:449-457.
10. Ben-Ezra J, Johnson DA, Rossi J, Cook N, Wu A. Effect of fixation on the amplification of nucleic acids from paraffin-embedded material by the polymerase chain reaction. Journal of Histochemistry & Cytochemistry 1991; 39:351-354.
11. Klimecki WT, Futscher BW, Dalton WS. Effects of ethanol and paraformaldehyde on RNA yield and quality. Biotechniques 1994; 16:1021-1023.
12. Ahram M, Flaig MJ, Gillespie JW, Duray PH, Linehan WM, Ornstein DK, Niu S, Zhao Y, Petricoin EF, 3rd, Emmert-Buck MR. Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics 2003; 3:413-421, DOI: 10.1002/pmic.200390056.
13. Gannot G, Tangrea MA, Gillespie JW, Erickson HS, Wallis BS, Leakan RA, Knezevic V, Hartmann DP, Chuaqui RF, Emmert-Buck MR. Layered peptide arrays: high-throughput antibody screening of clinical samples. Journal of Molecular Diagnostics 2005; 7:427-436, DOI: 10.1016/S1525-1578(10)60573-9.
14. Perlmutter MA, Best CJ, Gillespie JW, Gathright Y, Gonzalez S, Velasco A, Linehan WM, Emmert-Buck MR, Chuaqui RF. Comparison of snap freezing versus ethanol fixation for gene expression profiling of tissue specimens. Journal of Molecular Diagnostics 2004; 6:371-377.
15. Stanta G, Mucelli SP, Petrera F, Bonin S, Bussolati G. A novel fixative improves opportunities of nucleic acids and proteomic analysis in human archive's tissues. Diagnostic Molecular Pathology 2006; 15:115-123. DOI: 00019606-200606000-00009.
16. Gilbert MT, Haselkorn T, Bunce M, Sanchez JJ, Lucas SB, Jewell LD, Van Marck E, Worobey M. The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when? PLoS One 2007; 2:e537, DOI: 10.1371/journal.pone.0000537.
17. Vaught JB. Biorepository and biospecimen science: a new focus for CEBP. Cancer Epidemiology, Biomarkers & Prevention 2006; 15:1572-1573. DOI: 10.1158/1055-9965.EPI-06-0632.
18. Erickson HS, Josephson JW, Vira M, Albert PS, Gillespie JW, Rodriguez-Canales J, Pinto PA, Chuaqui RF, Emmert-Buck MR, Coleman JA. Influence of hypoxia induced by minimally invasive prostatectomy on gene expression: implications for biomarker analysis. American Journal of Translational Research 2010; 2:210-222.
19. Harrell JC, Dye WW, Harvell DM, Sartorius CA, Horwitz KB. Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases. Clinical and Experimental Metastasis 2008; 25:81-88. DOI: 10.1007/s10585-007-9105-7.
20. Rodriguez-Canales J, Hanson JC, Tangrea MA, Erickson HS, Albert PS, Wallis BS, Richardson AM, Pinto PA, Linehan WM, Gillespie JW, Merino MJ, Libutti SK, Woodson KG, Emmert-Buck MR, Chuaqui RF. Identification of a unique epigenetic sub-microenvironment in prostate cancer. The Journal of Pathology 2007; 211:410-419. DOI: 10.1002/path.2133.
21. Richardson AM, Woodson K, Wang Y, Rodriguez-Canales J, Erickson HS, Tangrea MA, Novakovic K, Gonzalez S, Velasco A, Kawasaki ES, Emmert-Buck MR, Chuaqui RF, Player A. Global expression analysis of prostate cancer-associated stroma and epithelia. Diagnostic Molecular Pathology 2007; 16:189-197. DOI: 10.1097/PDM.0b013e3180de20ac.
22. Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. Jouranl of Clinical Oncology 2005; 23:3219-3226. DOI: 10.1200/JCO.2005.15.511.
23. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450:893-898. DOI: 10.1038/nature06358.
24. Speer R, Wulfkuhle J, Espina V, Aurajo R, Edmiston KH, Liotta LA, Petricoin EF, 3rd. Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. Cancer Genomics & Proteomics 2007; 4:157-164.
25. Amann JM, Chaurand P, Gonzalez A, Mobley JA, Massion PP, Carbone DP, Caprioli RM. Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clinical Cancer Research 2006; 12:5142-5150. DOI: 10.1158/1078-0432.
26. Krishnamurthy S. Applications of molecular techniques to fine-needle aspiration biopsy. Cancer 2007; 111:106-122. DOI: 10.1002/cncr.22489.
27. Bieli C, Frei R, Schickinger V, Steinle J, Bommer C, Loeliger S, Braun-Fahrlander C, von Mutius E, Pershagen G, Lauener R. Gene expression measurements in the context of epidemiological studies. Allergy 2008; 63:1633-1636. DOI: 10.1111/j.1398-9995.2008.01744.x.
28. Holland NT, Pfleger L, Berger E, Ho A, Bastaki M. Molecular epidemiology biomarkers-sample collection and processing considerations. Toxicology and Applied Pharmacology 2005; 206:261-268. DOI: 10.1016/j.taap.2004.10.024.
29. Duramad P, McMahon CW, Hubbard A, Eskenazi B, Holland NT. Flow cytometric detection of intracellular TH1/TH2 cytokines using whole blood: validation of immunologic biomarker for use in epidemiologic studies. Cancer Epidemiology, Biomarkers & Prevention 2004; 13:1452-1458. DOI: 13/9/1452.
30. Lundblad RL. Considerations for the Use of Blood Plasma and Serum for Proteomic Analysis. The Internet Journal of Genomics and Proteomics 2005; 1(2).
31. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nature Genetics 2003; 33 Suppl:228-237. DOI: 10.1038/ng1090.
32. Bignell GR, Huang J, Greshock J, Watt S, Butler A, West S, Grigorova M, Jones KW, Wei W, Stratton MR, Futreal PA, Weber B, Shapero MH, Wooster R. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Research 2004; 14:287-295. DOI: 10.1101/gr.2012304.
33. Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Research 2004; 64:3060-3071.
34. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H, Brown EL. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nature Biotechnology 1996; 14:1675-1680. DOI: 10.1038/nbt1296-1675.
35. Matsuzaki H, Dong S, Loi H, Di X, Liu G, Hubbell E, Law J, Berntsen T, Chadha M, Hui H, Yang G, Kennedy GC, Webster TA, Cawley S, Walsh PS, Jones KW, Fodor SP, Mei R. Genotyping over 100, 000 SNPs on a pair of oligonucleotide arrays. Nature Methods 2004; 1:109-111. DOI: 10.1038/nmeth718.
36. Gunderson KL, Kruglyak S, Graige MS, Garcia F, Kermani BG, Zhao C, Che D, Dickinson T, Wickham E, Bierle J, Doucet D, Milewski M, Yang R, Siegmund C, Haas J, Zhou L, Oliphant A, Fan JB, Barnard S, Chee MS. Decoding randomly ordered DNA arrays. Genome Research 2004; 14:870-877. DOI: 10.1101/gr.2255804.
37. Gunderson KL, Steemers FJ, Lee G, Mendoza LG, Chee MS. A genome-wide scalable SNP genotyping assay using microarray technology. Nature Genetics 2005; 37:549-554. DOI: 10.1038/ng1547.
38. Dutt A, Beroukhim R. Single nucleotide polymorphism array analysis of cancer. Current Opinion in Oncology 2007; 19:43-49. DOI: 10.1097/CCO.0b013e328011a8c1.
39. Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RL, Shim J, Kantoff PW, Loda M, Meyerson M, Sellers WR. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Research 2003; 63:4781-4785.
40. Dumur CI, Dechsukhum C, Ware JL, Cofield SS, Best AM, Wilkinson DS, Garrett CT, Ferreira-Gonzalez A. Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics 2003; 81:260-269. DOI: S088875430300020X.
41. Lips EH, Dierssen JW, van Eijk R, Oosting J, Eilers PH, Tollenaar RA, de Graaf EJ, van't Slot R, Wijmenga C, Morreau H, van Wezel T. Reliable high-throughput genotyping and loss-of-heterozygosity detection in formalin-fixed, paraffin-embedded tumors using single nucleotide polymorphism arrays. Cancer Research 2005; 65:10188-10191, DOI: 10.1158/0008-5472.CAN-05-2486.
42. Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt SM, Duray PH, Herring J, Wang QH, Hu N, Linehan WM, Taylor PR, Liotta LA, Emmert-Buck MR, Petricoin EF, 3rd. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Research 2000; 60:6293-6297.
43. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nature Medicine 2001; 7:493-496. DOI: 10.1038/86573.
44. Cazares LH, Adam BL, Ward MD, Nasim S, Schellhammer PF, Semmes OJ, Wright GL, Jr. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clinical Cancer Research 2002; 8:2541-2552.
45. Chaurand P, Caprioli RM. Direct profiling and imaging of peptides and proteins from mammalian cells and tissue sections by mass spectrometry. Electrophoresis 2002; 23:3125-3135.
46. Petricoin EF, 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA. Serum proteomic patterns for detection of prostate cancer. Journal of the National Cancer Institute 2002; 94:1576-1578.
47. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003; 362:433-439. DOI: 10.1016/S0140-6736(03)14068-8.
48. Cheung PK, Woolcock B, Adomat H, Sutcliffe M, Bainbridge TC, Jones EC, Webber D, Kinahan T, Sadar M, Gleave ME, Vielkind J. Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Research 2004; 64:5929-5933. DOI: 10.1158/0008-5472.
49. Schwartz SA, Weil RJ, Johnson MD, Toms SA, Caprioli RM. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clinical Cancer Research 2004; 10:981-987.
50. Jaremko M, Justenhoven C, Abraham BK, Schroth W, Fritz P, Brod S, Vollmert C, Illig T, Brauch H. MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET). Human Mutation 2005; 25:232-238. DOI: 10.1002/humu.20141.
51. Erickson HS, Albert PS, Gillespie JW, Wallis BS, Rodriguez-Canales J, Linehan WM, Gonzalez S, Velasco A, Chuaqui RF, Emmert-Buck MR. Assessment of normalization strategies for quantitative RT-PCR using microdissected tissue samples. Laboratory Investigation 2007; 87:951-962, DOI: 10.1038/labinvest.3700659.
52. Erickson HS, Albert PS, Gillespie JW, Rodriguez-Canales J, Marston Linehan W, Pinto PA, Chuaqui RF, Emmert-Buck MR. Quantitative RT-PCR gene expression analysis of laser microdissected tissue samples. Nature Protocols 2009; 4:902-922, DOI: 10.1038/nprot.2009.61.
53. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Molecular Cancer 2006; 5:24. DOI: 10.1186/1476-4598-5-24.
54. Micke P, Kappert K, Ohshima M, Sundquist C, Scheidl S, Lindahl P, Heldin CH, Botling J, Ponten F, Ostman A. In situ identification of genes regulated specifically in fibroblasts of human basal cell carcinoma. Journal of Investigative Dermatology 2007; 127:1516-1523. DOI: 10.1038/sj.jid.5700714.
55. Zhao H, Ramos CF, Brooks JD, Peehl DM. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. Journal of Cellular Physiology 2007; 210:111-121. DOI: 10.1002/jcp.20828.
56. Morrison T, Hurley J, Garcia J, Yoder K, Katz A, Roberts D, Cho J, Kanigan T, Ilyin SE, Horowitz D, Dixon JM, Brenan CJ. Nanoliter high throughput quantitative PCR. Nucleic Acids Research 2006; 34:e123, DOI: 10.1093/nar/gkl639.
57. Thorsen T, Maerkl SJ, Quake SR. Microfluidic large-scale integration. Science 2002; 298:580-584. DOI: 10.1126/science.1076996.
58. Martel RR, Botros IW, Rounseville MP, Hinton JP, Staples RR, Morales DA, Farmer JB, Seligmann BE. Multiplexed screening assay for mRNA combining nuclease protection with luminescent array detection. Assay and Drug Development Technology 2002; 1:61-71. DOI: 10.1089/154065802761001310.
59. Cheng Q, Lau WM, Tay SK, Chew SH, Ho TH, Hui KM. Identification and characterization of genes involved in the carcinogenesis of human squamous cell cervical carcinoma. International Journal of Cancer 2002; 98:419-426. DOI: 10.1002/ijc.10177.
60. Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene 2003; 22:6497-6507. DOI: 10.1038/sj.onc.1206865.
61. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412:822-826. DOI: 10.1038/35090585.
62. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Research 2001; 61:4683-4688.
63. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, Finkelstein S, Michalopoulos G, Becich M. Gene expression analysis of prostate cancers. Molecular Carcinogenesis 2002; 33:25-35. DOI: 10.1002/mc.10018.
64. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Jr., Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Research 2001; 61:5974-5978.
65. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1:203-209. DOI: S1535610802000302.
66. Best CJ, Leiva IM, Chuaqui RF, Gillespie JW, Duray PH, Murgai M, Zhao Y, Simon R, Kang JJ, Green JE, Bostwick DG, Linehan WM, Emmert-Buck MR. Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagnostic Molecular Pathology 2003; 12:63-70.
67. Best CJ, Gillespie JW, Yi Y, Chandramouli GV, Perlmutter MA, Gathright Y, Erickson HS, Georgevich L, Tangrea MA, Duray PH, Gonzalez S, Velasco A, Linehan WM, Matusik RJ, Price DK, Figg WD, Emmert-Buck MR, Chuaqui RF. Molecular alterations in primary prostate cancer after androgen ablation therapy. Clinical Cancer Research 2005; 11:6823-6834. DOI: 10.1158/1078-0432.CCR-05-0585.
68. Ma S, Guan XY, Beh PS, Wong KY, Chan YP, Yuen HF, Vielkind J, Chan KW. The significance of LMO2 expression in the progression of prostate cancer. The Journal of Pathology 2007; 211:278-285. DOI: 10.1002/path.2109.
69. Printz C. BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery. Cancer 2010; 116:3307-3308. DOI: 10.1002/cncr.25493.
70. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ. High density synthetic oligonucleotide arrays. Nature Genetics 1999; 21:20-24. DOI: 10.1038/4447.
71. Xie Y, Xiao G, Coombes KR, Behrens C, Solis LM, Raso G, Girard L, Erickson HS, Roth J, Heymach JV, Moran C, Danenberg K, Minna JD, Wistuba II. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clinical Cancer Research 2011; 17:5705-5714. DOI: 1078-0432.CCR-11-0196.
72. Ge H. UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions. Nucleic Acids Research 2000; 28:e3.
73. Liotta L, Petricoin E. Molecular profiling of human cancer. Nature Reviews Genetics 2000; 1:48-56, DOI: 10.1038/35049567:10.1038/35049567.
74. MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science 2000; 289:1760-1763.
75. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE, Liotta LA. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20:1981-1989. DOI: 10.1038/sj.onc.1204265.
76. Zhu H, Snyder M. Protein arrays and microarrays. Current Opinion in Chemical Biology 2001; 5:40-45. DOI: S1367-5931(00)00170-8.
77. Zhu H, Snyder M. Protein chip technology. Current Opinion in Chemical Biology 2003; 7:55-63. DOI: S1367593102000054.
78. Charboneau L, Tory H, Chen T, Winters M, Petricoin EF, 3rd, Liotta LA, Paweletz CP. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Briefings in Functional Genomics and Proteomics 2002; 1:305-315.
79. Lal SP, Christopherson RI, dos Remedios CG. Antibody arrays: an embryonic but rapidly growing technology. Drug Discovery Today 2002; 7:S143-149. DOI: S1359644602024133.
80. MacBeath G. Protein microarrays and proteomics. Nature Genetics 2002; 32 Suppl:526-532. DOI: 10.1038/ng1037.
81. Cutler P. Protein arrays: the current state-of-the-art. Proteomics 2003; 3:3-18. DOI: 10.1002/pmic.200390007.
82. Grubb RL, Calvert VS, Wulkuhle JD, Paweletz CP, Linehan WM, Phillips JL, Chuaqui R, Valasco A, Gillespie J, Emmert-Buck M, Liotta LA, Petricoin EF. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 2003; 3:2142-2146. DOI: 10.1002/pmic.200300598.
83. Liotta LA, Espina V, Mehta AI, Calvert V, Rosenblatt K, Geho D, Munson PJ, Young L, Wulfkuhle J, Petricoin EF, 3rd. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003; 3:317-325. DOI: S1535610803000862.
84. Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, Petricoin EF, 3rd. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003; 3:2085-2090, DOI: 10.1002/pmic.200300591.
85. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. Journal of Thoracic Oncology 2011; 5:1894-1904.
86. Jacobson JW, Oliver KG, Weiss C, Kettman J. Analysis of individual data from bead-based assays ("bead arrays"). Cytometry A 2006; 69:384-390. DOI: 10.1002/cyto.a.20293.
87. Stillman BA, Tonkinson JL. FAST slides: a novel surface for microarrays. Biotechniques 2000; 29:630-635.
88. Tonkinson JL, Stillman BA. Nitrocellulose: a tried and true polymer finds utility as a post-genomic substrate. Frontiers in Bioscience 2002; 7:c1-12.
89. Espina V, Mehta AI, Winters ME, Calvert V, Wulfkuhle J, Petricoin EF, 3rd, Liotta LA. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 2003; 3:2091-2100. DOI: 10.1002/pmic.200300592.
90. Pelech S. Tracking cell signaling protein expression and phosphorylation by innovative proteomic solutions. Current Pharmaceutical Biotechnology 2004; 5:69-77.
91. Lee LJ, Yang ST, Lai S, Bai Y, Huang WC, Juang YJ. Microfluidic enzyme-linked immunosorbent assay technology. Advances in Clinical Chemistry 2006; 42:255-295.
92. Edenberg HJ, Liu Y. Laboratory methods for high-throughput genotyping. Cold Spring Harbor Protocols 2009; 4(1):1-9. DOI: 10.1101/pdb.top62.
93. Bansal A, van den Boom D, Kammerer S, Honisch C, Adam G, Cantor CR, Kleyn P, Braun A. Association testing by DNA pooling: an effective initial screen. Proceedings of the National Academy of Sciences of the United States of America 2002; 99:16871-16874. DOI: 10.1073/pnas.262671399.
94. Sham P, Bader JS, Craig I, O'Donovan M, Owen M. DNA Pooling: a tool for large-scale association studies. Nature Reviews Genetics 2002; 3:862-871. DOI: 10.1038/nrg930.
95. Kendziorski C, Irizarry RA, Chen KS, Haag JD, Gould MN. On the utility of pooling biological samples in microarray experiments. Proceedings of the National Academy of Sciences of the United States of America 2005; 102:4252-4257. DOI: 10.1073/pnas.0500607102.
96. Cheung VG, Conlin LK, Weber TM, Arcaro M, Jen KY, Morley M, Spielman RS. Natural variation in human gene expression assessed in lymphoblastoid cells. Nature Genetics 2003; 33:422-425. DOI: 10.1038/ng1094.
97. Liu A, Schisterman EF. Comparison of Diagnostic Accuracy of Biomarkers With Pooled Assessments. In Comparison of Diagnostic Accuracy of Biomarkers With Pooled Assessments. WILEY-VCH Verlag: New York, 2003; 631-644.
98. Farrington CP. Estimating prevalence by group testing using generalized linear models. Statistics in Medicine 1992; 11:1591-1597.
99. Barcellos LF, Klitz W, Field LL, Tobias R, Bowcock AM, Wilson R, Nelson MP, Nagatomi J, Thomson G. Association mapping of disease loci, by use of a pooled DNA genomic screen. American Journal of Human Genetics 1997; 61:734-747, DOI: 10.1086/515512.
100. Weinberg CR, Umbach DM. Using pooled exposure assessment to improve efficiency in case-control studies. Biometrics 1999; 55:718-726.
101. Telaar A, Nurnberg G, Repsilber D. Finding biomarker signatures in pooled sample designs: a simulation framework for methodological comparisons. Advances in Bioinformatics 2010:318573. DOI: 10.1155/2010/318573.
102. Allison DB, Cui X, Page GP, Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nature Reviews Genetics 2006; 7:55-65, DOI: 10.1038/nrg1749.
103. Kerr MK. Design considerations for efficient and effective microarray studies. Biometrics 2003; 59:822-828.
104. Kainkaryam RM, Bruex A, Gilbert AC, Schiefelbein J, Woolf PJ. poolMC: smart pooling of mRNA samples in microarray experiments. BMC Bioinformatics; 11:299. DOI: 10.1186/1471-2105-11-299.
105. Schmechel SC, LeVasseur RJ, Yang KH, Koehler KM, Kussick SJ, Sabath DE. Identification of genes whose expression patterns differ in benign lymphoid tissue and follicular, mantle cell, and small lymphocytic lymphoma. Leukemia 2004; 18:841-855. DOI: 10.1038/sj.leu.2403293.
106. Yang HC, Liang YJ, Huang MC, Li LH, Lin CH, Wu JY, Chen YT, Fann CS. A genome-wide study of preferential amplification/hybridization in microarray-based pooled DNA experiments. Nucleic Acids Research 2006; 34:e106. DOI: 10.1093/nar/gkl446.
107. Johnson C, Drgon T, Liu QR, Walther D, Edenberg H, Rice J, Foroud T, Uhl GR. Pooled association genome scanning for alcohol dependence using 104, 268 SNPs: validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2006; 141B:844-853. DOI: 10.1002/ajmg.b.30346.
108. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, Schulze TG, Cichon S, Rietschel M, Nothen MM, Georgi A, Schumacher J, Schwarz M, Abou Jamra R, Hofels S, Propping P, Satagopan J, Detera-Wadleigh SD, Hardy J, McMahon FJ. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Molecular Psychiatry 2008; 13:197-207. DOI: 10.1038/sj.mp.4002012.